Radiological diagnostics in patients with pheochromocytoma – do we need to prepare? Review of the literature
DOI:
https://doi.org/10.12775/JEHS.2020.10.09.094Keywords
pheochromocytoma, adrenals glands, contrast agent, incidentalomas, radiology.Abstract
Introduction: Pheochromocytomas are chromaffin cell tumours derived from the neural crest and they are associated with catecholamine production. Radiological procedures are playing essential role in present diagnostic of adrenal glands. Physicians who send their patients to the radiological examinations should prepare them to have a safe further diagnostic. Aa well radiologist should be aware of scanning protocols to provide best quality and the safest for the patient radiological examination.
Aim of the study: This article summarizes the current knowledge about radiological imaging of pheochromocytomas and scan procedures. In this paper we also want to answer to the question does a patient with pheochromocytoma need to be specially prepared for radiological procedures.
Description of knowledge: Diagnostic procedures play primary role in present diagnostic and treatment of pheochomocytomas. It is crucial for further diagnostic procedures to locate the tumour and its margins.Ultrasound imaging can be used with success only in big tumours with clinical symptoms. First choice for adrenal gland tumours is always CT. That modality easily shows localisation and tumours smaller than 1 cm. Another method of choice for adrenal imaging is MRI which gives high contrast images between soft tissues. Radiological differentiation of lessions wouldn’t be possible without contrast agents. They are crucial for calculations of washout in CT.
Conclusions: Intravenous administration of non-ionic contrast agent for CT and gadolinium based in MRI is a safe practice for patients with pheos even without α-blocking medication. Only in an intra-arterial iodine-based contrast administration patient should be pharmacologically prepared before examination.
References
Pacak K and Wimalawansa SJ: Pheochromocytoma and paraganglioma. Endocr. Pract. 2015.
Farrugia FA and charalampopoulos A: Pheochromocytoma. Endocr. Regul. 2019; 53: 191–212.
Dahia PLM: Pheochromocytomas and Paragangliomas, Genetically Diverse and Minimalist, All at Once! Cancer Cell 2017.
Kiernan CM and Solórzano CC: Pheochromocytoma and Paraganglioma. Diagnosis, Genetics, and Treatment. Surg. Oncol. Clin. N. Am. 2016; 25: 119–138. Available at: http://dx.doi.org/10.1016/j.soc.2015.08.006.
Pamporaki C, Hamplova B, Peitzsch M, et al: Characteristics of pediatric vs adult pheochromocytomas and paragangliomas. J. Clin. Endocrinol. Metab. 2017.
Landsberg L: Clinical features of pheochromocytoma and paraganglioma. In: Contemporary Endocrinology. 2018.
Manger WM: The protean manifestations of pheochromocytoma. Horm. Metab. Res. 2009.
Farrugia FA, Martikos G, Tzanetis P, et al: Pheochromocytoma, diagnosis and treatment: Review of the literature. Endocr. Regul. 2017; 51: 168–181.
Gunawardane PTK and Grossman A: The clinical genetics of phaeochromocytoma and paraganglioma. Arch. Endocrinol. Metab. 2017.
Arnaldi G, Masini AM, Giacchetti C, et al: Adrenal incidentaloma. Brazilian J. Med. Biol. Res. 2000.
Pappachan JM, Raskauskiene D, Sriraman R, Edavalath M, Hanna FW. et al: Diagnosis and management of pheochromocytoma: A practical guide to clinicians. Curr. Hypertens. Rep. 2014.
Naranjo J, Dodd S and Martin YN: Perioperative Management of Pheochromocytoma. J. Cardiothorac. Vasc. Anesth. 2017; 31: 1427–1439. Available at: http://dx.doi.org/10.1053/j.jvca.2017.02.023.
Bednarczuk.T, Bolanowski.M, Sworczak.K, et al: Adrenal incidentaloma in adults - Management recommendations by the Polish Society of Endocrinology. Endokrynol. Pol. 2016. Polish
Goldstein RE, O’Neill JA, Holcomb GW, et al: Clinical experience over 48 years with pheochromocytoma. In: Annals of Surgery. 1999.
Hack HA: The perioperative management of children with phaeochromocytoma. Paediatr. Anaesth. 2000.
Chen H, Sippel RS, O'Dorisio MS, Vinik AI, Lloyd RV, Pacak K: The north american neuroendocrine tumor society consensus guideline for the diagnosis and management of neuroendocrine tumors: Pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 2010.
Gagner M, Pomp A, Todd Heniford B, et al: Laparoscopic adrenalectomy: Lessons learned from 100 consecutive procedures. Ann. Surg. 1997; 226: 238–247.
Baudin E: Treatment of malignant pheochromocytomas and paragangliomas. Endocr. Abstr. 2013.
Shulkin BL, Ilias I, Sisson JC, et al: Current trends in functional imaging of pheochromocytomas and paragangliomas. Ann. N. Y. Acad. Sci. 2006; 1073: 374–382.
Ramachandran R and Rewari V: Current perioperative management of pheochromocytomas. Indian J. Urol. 2017.
Bowerman RA, Silver TM, Jaffe MH, et al: Sonography of adrenal pheochromocytomas. Am. J. Roentgenol. 1981; 137: 1227–1231.
Lenders JWM, Duh QY, Eisenhofer G, et al: Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2014; 99: 1915–1942.
Varatorn R and Suchato C: Sabiston Textbook of Surgery The Biological Basis of Modern Surgical Practice 19th Edition 2012. Bangkok Med. J. 2012.
Miyake H, Maeda H, Tashiro M, et al: CT of adrenal tumors: Frequency and clinical significance of low-attenuation lesions. Am. J. Roentgenol. 1989.
Lee JK: Computed Body Tomography with MRI correlation.; 1998.
Elsayes KM, Mukundan G, Narra VR, et al: Adrenal masses: MR imaging features with pathologic correlation. Radiographics 2004.
Schteingart DE, Doherty GM, Gauger PG, et al: Management of patients with adrenal cancer: Recommendations of an international consensus conference. In: Endocrine-Related Cancer. 2005.
Contrast Media Safety Committee: ESUR Guidelines on Contrast Agents v10.0. Eur. Soc. Urogenit. Radiol. 2018.
Downloads
Published
How to Cite
Issue
Section
License
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 409
Number of citations: 0